Lupus
Q&A: CD6/ALCAM may hold key to more specific, effective therapies in lupus nephritis
Uncovering a viable biomarker in a historically challenging disease like lupus nephritis is tantamount to striking gold if it can be used for one important purpose: Predicting treatment response.
Social media may highlight research needs, clinical care gaps in lupus
Patient-generated data gathered via social media surveillance may highlight unmet research needs and clinical care gaps for patients with lupus, including underrepresented groups, according to data published in Arthritis Care and Research.
Worse COVID-19 outcomes in lupus driven by demographics, untreated disease
Worse COVID-19 outcomes in patients with systemic lupus erythematosus are driven by comorbidities, demographics and untreated or active disease, according to data published in the Annals of the Rheumatic Diseases.
Lupus doubles risk for gestational diabetes during pregnancy
Patients with systemic lupus erythematosus are at double the risk for gestational diabetes during pregnancy compared with those without SLE, according to data published in The Journal of Rheumatology.
Nearly 25% of children with systemic lupus erythematosus develop growth impairment
Growth impairment was reported in 23.6% of children with systemic lupus erythematosus, with corticosteroid duration and exposure prior to late puberty identified as key risk factors, according to data published in Pediatric Rheumatology.
Anifrolumab reduces lupus disease activity across musculoskeletal, mucocutaneous domains
Anifrolumab improves systemic lupus erythematosus disease activity across musculoskeletal, mucocutaneous and immunological domains, according to a post-hoc analysis of TULIP-1 and TULIP-2 data published in The Lancet Rheumatology.
AKF launches new campaign for prevention, management of lupus nephritis
African American women with lupus at higher risk for adverse perinatal outcomes
African American women with systemic lupus erythematosus were found to be at increased risk for preterm and small-for-gestational age births, even prior to clinical diagnosis, according to data published in Arthritis Care & Research.
Current hydroxychloroquine use linked to reduced cardiovascular risk in lupus, RA
Current hydroxychloroquine use in patients with rheumatoid arthritis or systemic lupus erythematosus is associated with a reduced risk for cardiovascular events, including ischemic stroke and myocardial infarction, according to data.
'Waste of energy': One-third of connective tissue disease RCTs never completed, published
One out of three registered randomized controlled trials on connective tissue diseases are never completed or published, representing a “waste of energy or resources” that may skew meta-analyses, according to researchers.